Pembrolizumab after ASCT in PTCL, germline predisposition to myeloid neoplasms in patients with hypoplastic bone marrow, and limited plasticity of monocyte fate and function
This episode covers pembrolizumab's use in PTCL post-ASCT, finding a favorable safety profile and promising activity. It also discusses germline mutations linked to myeloid neoplasms in hypoplastic bone marrow and research suggesting limited plasticity in monocyte fate after…